Novartis Capabilities Update October 2026: Small Molecule Drug Substance

Scaling small molecule therapies requires dynamic manufacturing capacity, technical versatility, and strict regulatory alignment across every phase of commercialization. Integrating complex synthetic chemistries—such as oligonucleotide synthesis, continuous flow processing, cryogenic cooling, and preparative chromatography—into a unified global production network minimizes vendor friction and accelerates time-to-market. By leveraging multi-site operational flexibility across North America and Europe, drug developers can seamlessly reallocate production volumes to adapt to shifting demand while maintaining uniform quality standards and supporting ambitious sustainability targets. Accessing high-containment processing and specialized particle engineering within a single regulatory framework strengthens supply chain resilience from initial clinical scale-up through long-term commercial supply.

Explore the full presentation to learn how aligned technical transfers and dedicated project governance optimize small molecule manufacturing strategies.